Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.France-based Provepharm and Martindale Pharma of UK have entered a partnership to supply Provepharm's injectable medicinal product, methylthioninium chloride Proveblue solution for injection (Proveblue), to treat methaemoglobinaemia in the UK and Ireland.
Subscribe to our email newsletter
As per the terms of the partnership, Martindale Pharma will take charge of commercial activities relating to Proveblue in the UK and Ireland.
The commercial terms of the agreement have not been disclosed.
According to the company, Proveblue is beneficial as it includes a new indication for chemical products-induced methaemoglobinaemia, and acute symptomatic treatment of medicinal methaemoglobinaemia besides the indication to treat children, adolescents and adults.
Provepharm CEO and founder Michel Feraud said Martindale has a good understanding of their market in the UK and Ireland and their shift to Proveblue would help enhance quality for patients.